Turn-off fluorescent magnetic Mn-ZnS molecularly imprinted probe for the detection of chlorpyrifos in vegetable samples.

A sensitive and efficient fluorescent sensor based on a magnetic manganese-doped zinc sulfide molecularly imprinted probe (FeO/Mn-ZnS/MIP) was successfully developed for the detection of chlorpyrifos (CPF). The probe combined the advantages of magnetic separation, the fluorescence properties of Mn-ZnS, and the exceptional molecule recognition capabilities of molecularly imprinted polymers. The developed sensor exhibits selective binding to CPF, resulting in a quenching of fluorescence intensity of FeO/Mn-ZnS/MIP by a photo-induced electron transfer mechanism.

Current trends of functional monomers and cross linkers used to produce molecularly imprinted polymers for food analysis.

Molecularly imprinted polymers (MIPs) as artificial synthetic receptors are in high demand for food analysis due to their inherent molecular recognition abilities. It is common practice to employ functional monomers with basic or acidic groups that can interact with analyte molecules hydrogen bonds, covalent bonds, and other interactions (π-π, dipole-ion, hydrophobic, and Van der Waals). Therefore, selecting the appropriate functional monomer and cross-linker is crucial for determining how precisely they interact with the template and developing the polymeric network's three-dimensional structure.

Polymethyl Methacrylate for Elbow Arthroplasty: Is There Another Way?

Polymethyl methacrylate remains the only US Food and Drug Administration-approved method of total elbow arthroplasty fixation and exhibits high aseptic loosening rates that result in challenging revision surgeries and potential morbidity secondary to bone-cement implantation syndrome. In this policy paper, the authors aim to explore the historical background of polymethyl methacrylate and the complications that arise in association with its use. We will review arthroplasty trends in the elbow and lower extremities and the challenges with the US Food and Drug Administration-approval process.

Drug-coated balloons for coronary artery disease: An updated review with future perspectives.

Since the advent of coronary stents, two of the most common long-term complications after percutaneous coronary intervention (PCI) are in-stent restenosis (ISR) and stent thrombosis (ST). Although the rates of ST have been nearly abolished and ISR rates have declined with the current gold-standard second-generation drug-eluting stents (DES), late ISR of DES remains a valid concern in the field of interventional cardiology. The drug-coated balloon (DCB) is a non-stent technology that relies on the concept of targeted homogeneous drug delivery from an inflated balloon to restore luminal vascularity, treat atherosclerosis, and overcome some limitations of PCI, including ISR and prolonged dual antiplatelet therapy to prevent ST by leaving nothing behind.